bottom-blue top-blue

PostHeaderIcon Current Clinical Trials

Corneal Crosslinking (CXL) Clinical Trial for
Keratoconus and Ectasia - Now Open

We are recruiting patients with progressive keratoconus or ectasia after LASIK for a clinical trial with an IDE from the FDA to compare the effectiveness of collagen cross linking alone to INTACS followed by collagen cross-linking as a potential treatment for progressive keratoconus or Ectasia after Lasik.

If you are interested and think you qualify, please contact Dr. Maguen:

American Eye Institute, Cedars-Sinai Medical Towers
8635 W. 3rd Street., Suite 390W - Los Angeles, CA 90048

Our study uses the same technology and methodology used in Europe. It was first described by Dr. Theo Seiler and colleagues several years ago and which now with long term follow up suggests halting or reversal or of the progression of keratoconus. Preliminary reports in the literature suggests that a combination of INTACS plus cross linking is more efficacious effective than cross linking alone.

The purpose of our study is to determine which methodology is better for halting the progression of ectasia.

To be eligible patients need to :

  1. have a diagnosis of keratoconus or ectasia after lasik
  2. have demonstrated progression of at least 1 Diopter in a 1 year period and
  3. have a corneal thickness of at least 400um or more.

Patients can be referred by phone to 310.652.1133 or by email to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

For more information about Corneal Crosslinking, click here.